酚二唑 | 1008-65-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 酚二唑
• 中文别名: 2-(1,3,4-二唑-2-基)苯酚；2-(1,3,4-二唑基)苯酚；2-(1,3,4-氧二唑-2-基)苯酚；2-(1,3,4-噁二唑-2-基)苯酚
• 英文名称: 2-(1,3,4-oxadiazol-2-yl)-phenol
• 英文别名: 2-(2-hydroxyphenyl)-1,3,4-oxadiazole；2-(1,3,4-oxadiazol-2-yl)phenol；2-[1,3,4]oxadiazol-2-yl-phenol；2-([1,3,4]Oxadiazol-2-yl)phenol；fenadiazole；2-<2-Hydroxy-phenyl>-1,3,4-oxdiazol
• CAS: 1008-65-7
• 化学式: C₈H₆N₂O₂
• mdl: MFCD00020713
• 分子量: 162.148
• InChiKey: OINXXHYENYVYPB-UHFFFAOYSA-N

物化性质

• 熔点：
  100 °C
• 沸点：
  bp0.1 180°
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	2-(1 3 4-Oxadiazol-2-yl)phenol 97% Material Safety Data Sheet
Synonym:
CAS:	1008-65-7

Section 1 - Chemical Product MSDS Name:2-(1 3 4-Oxadiazol-2-yl)phenol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1008-65-7	2-(1,3,4-Oxadiazol-2-yl)phenol	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1008-65-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 108 - 110 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6N2O2
Molecular Weight: 162.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1008-65-7: SM5850000 LD50/LC50:
Not available.
Carcinogenicity:
2-(1,3,4-Oxadiazol-2-yl)phenol - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 1008-65-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1008-65-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1008-65-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  酚二唑 在 sodium ethanolate 作用下， 生成 (2-[1,3,4]oxadiazol-2-yl-phenoxy)-acetic acid methyl ester
  参考文献：
  名称：

  Vincent,M., Bulletin de la Societe Chimique de France, 1962, p. 1587 - 1591

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲酰水杨酰肼 在 三氯氧磷 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 16.0h， 以65%的产率得到酚二唑
  参考文献：
  名称：

  水杨酸肼的某些杂环化合物的合成及生物评价

  摘要：

  从2-羟基苯甲酰肼开始制备了各种杂环化合物；例如，酰肼腙环化3由2- hydroxybenzohydrazide衍生2用乙酸酐或浓硫酸，得到1,3,4-恶二唑衍生物4 - 5。在另一方面，2-羟基苯甲酰肼的环化直接2与一个碳环化剂得到的1,3,4-恶二唑的新衍生7，8，9，10，11。用吡啶中的巯基乙酸对酰肼3进行加热，得到噻唑烷酮12。当2-羟基苯甲酰肼2与脂肪族羧酸（例如甲酸或乙酸）反应时，得到相应的N-甲酰基或N-乙酰基衍生物6。随后在吡啶中使用五硫化二磷对6进行环化，得到1,3,4-噻二唑13。2-羟基苯并肼与乙酰乙酸乙酯的环化反应得到吡唑啉酮衍生物14。最后，当在35％HCl中用硫氰酸铵处理酰肼2的乙醇溶液时，得到硫代氨基脲15。后续治疗15用浓硫酸或10％氢氧化钠溶液分别制得5-氨基-1,3,4-噻二唑16和1,2,4-三唑17。使用1 H NMR，IR光谱和元素分析确认了所有

  DOI：

  10.1002/jhet.2516

文献信息

• Aromatic amine derivative and use thereof
  申请人：Taniguchi Takahiko

  公开号：US20090325956A1

  公开（公告）日：2009-12-31

  The present invention provides a novel SCD inhibitor. An SCD inhibitor containing a compound represented by the formula [I] wherein ring A is an optionally substituted aromatic ring, ring B is an optionally substituted ring, ring C is an optionally substituted aromatic ring, R is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and X is a spacer having 1 to 5 atoms in the main chain, or a salt thereof, or a prodrug thereof.

  本发明提供了一种新型SCD抑制剂。一种包含由下式[I]表示的化合物的SCD抑制剂 其中环A是可选择取代的芳香环，环B是可选择取代的环，环C是可选择取代的芳香环，R是氢原子，可选择取代的碳氢基团或可选择取代的杂环基团，X是具有主链中1到5个原子的间隔物，或其盐，或其前药。
• Transition metal-free direct C–H bond thiolation of 1,3,4-oxadiazoles and related heteroarenes
  作者：Liang-Hua Zou、Jens Reball、Jakob Mottweiler、Carsten Bolm

  DOI：10.1039/c2cc36711d

  日期：——

  A convenient transition metal-free procedure for the direct thiolation of 1,3,4-oxadiazole C–H bonds using diaryl disulfides has been developed. Other substrates including indole, benzothiazole, N-phenylbenzimidazole, and caffeine were also thiolated in this manner, providing the corresponding products in good to excellent yields.

  开发了一种便捷的无过渡金属催化方法，利用二芳基二硫醚直接对1,3,4-噁二唑C-H键进行硫醇化。该方法同样适用于吲哚、苯并噻唑、N-苯基苯并咪唑及咖啡因等多种底物，能以良好至优异的产率得到相应的硫醇化产物。
• Electrophilic activation of nitroalkanes in efficient synthesis of 1,3,4-oxadiazoles
  作者：Alexander V. Aksenov、Vladislav Khamraev、Nicolai A. Aksenov、Nikita K. Kirilov、Dmitriy A. Domenyuk、Vladimir A. Zelensky、Michael Rubin

  DOI：10.1039/c9ra00976k

  日期：——

  A novel methodology for general and chemoselective preparation of non-symmetric 1,3,4-oxadiazoles is developed. This unusual reaction proceeds via polyphosphoric acid-assisted activation of nitroalkanes towards nucleophilic attack with acylhydrazides.

  开发了一种用于非对称 1,3,4-恶二唑的通用和化学选择性制备的新方法。这种不寻常的反应是通过多磷酸辅助的硝基烷烃活化向酰基肼的亲核攻击而进行的。
• Compounds enhancing antitumor activity of other cytotoxic agents
  申请人：Pfizer Inc

  公开号：US06130217A1

  公开（公告）日：2000-10-10

  This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).

  这项发明涉及某些杂环化合物及其药用可接受的盐，这些化合物对于使多药耐药肿瘤细胞对抗癌药物和多药耐药形式的疟疾、结核病、利什曼病和阿米巴痢疾对化疗药物具有敏感性是有用的。这些化合物及其药用可接受的盐还是人类MDR1基因编码的P-糖蛋白的活性药物转运能力的抑制剂，以及来自真核和原核生物（例如，来自疟原虫的pfmdr，以及小鼠mdr1和mdr3基因产物）的某些其他相关的ATP结合盒转运蛋白的抑制剂。
• Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
  申请人：Bezwada Rao S.

  公开号：US20120035259A1

  公开（公告）日：2012-02-09

  The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

  本发明提供了一氧化氮(NO)和可选的药物释放的大分子和寡聚物，其中药物分子和一氧化氮释放部分通过可吸收的大分子或可水解降解的寡聚物链连接，并且大分子或寡聚物由来自诸如乙醇酸、乳酸、己内酰胺和对二恶烷等安全且生物相容的分子的重复单元组成。此外，本发明还涉及从一氧化氮和/或药物分子释放的大分子或寡聚物控制释放一氧化氮(NO)。此外，本发明还涉及包含本发明的一氧化氮和药物释放大分子和寡聚物的医疗器械、医疗器械涂层和治疗方法。